0 items

in your cart
$0.00

  • Search for Medications
  • Viewcart | Checkout
  • Manage Account
  •  
  • Click-to-Call  

Prescription Drug Search

Strengths available for Lumiracoxib :

Lumiracoxib 100mg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about SaveRxCanada.to

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Lumiracoxib:

  • Armenia
  • Australia
  • Azerbaijan
  • Barbados
  • Belize
  • Bosnia and Herzegovina
  • Brazil
  • Bulgaria
  • Chile
  • Colombia
  • Costa Rica
  • Cyprus
  • Denmark
  • Finland
  • Germany
  • Gibraltar
  • Guam
  • Guatemala
  • Hong Kong
  • India
  • Indonesia
  • Iraq
  • Ireland
  • Korea, Republic of
  • Latvia
  • Malta
  • Netherlands
  • Panama
  • Paraguay
  • Peru
  • Qatar
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • Tonga
  • United Kingdom, UK
  • United States, US
  • Uruguay
  • Vietnam
View All Countries

Latest news releases on Lumiracoxib:

Lumiracoxib - Wikipedia

Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug.. Its structure is different from that of other COX-2 inhibitors, such as celecoxib: lumiracoxib is an analogue of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid class of NSAIDs; it binds to a different ...

Lumiracoxib - Drugs.com

Lumiracoxib Scheme. Rec.INN. ATC (Anatomical Therapeutic Chemical Classification) M01AH06. CAS registry number (Chemical Abstracts Service) 0220991-20-8. Chemical Formula. C15-H13-Cl-F-N-O2. Molecular Weight. 294. Therapeutic Categories. Analgesic, antipyretic and anti-inflammatory agent. Non-steroidal anti-inflammatory drug, NSAID. Cyclo ...

Lumiracoxib | C15H13ClFNO2 - PubChem

Lumiracoxib is an amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.

Lumiracoxib - DrugBank

Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.

European Medicines Agency - - Lumiracoxib

Lumiracoxib is used to relieve the signs of inflammation (pain, swelling and stiffness) in patients who have osteoarthritis of the knee or the hip (a disease in which the protective cartilage in the joints is worn down). Tablets containing 100 mg lumiracoxib have been available in a number of European Union (EU) countries since 2005.

Lumiracoxib - an overview | ScienceDirect Topics

Lumiracoxib 400 mg demonstrated the fastest time to analgesic onset (37.4min) followed by ibuprofen then lumiracoxib 100 mg (Zelenakas et al 2004). Following third molar extraction a single oral dose of lumiracoxib 400 mg was superior to rofecoxib 50 mg, celecoxib 200 mg or placebo at 8 hours post dose (Kellstein et al 2004).

Lumiracoxib – Wikipedia

Lumiracoxib ist ein Arzneistoff aus der Gruppe der Cyclooxygenase-2-Hemmer (auch COX-2-Hemmer oder Coxibe genannt), der in der Behandlung von Symptomen bei aktivierter Arthrose des Knie- und Hüftgelenks eingesetzt wurde. Im Unterschied zu den anderen selektiven COX-2-Hemmern ähnelt seine Struktur der von Diclofenac.

Lumiracoxib | European Medicines Agency

Lumiracoxib is used to relieve the signs of inflammation (pain, swelling and stiffness) in patients who have osteoarthritis of the knee or the hip (a disease in which the protective cartilage in the joints is worn down). Tablets containing 100 mg lumiracoxib have been available in a number of European Union (EU) countries since 2005.

Lumiracoxib: the evidence of its clinical impact on the ...

Lumiracoxib is metabolized by the cytochrome P450 isoform 2C9 (CYP 2C9) (Mangold et al. 2004; Rordorf et al. 2005). However, lumiracoxib has no significant pharmacokinetic interactions with the CYP 2C9 substrate, warfarin (Bonner et al. 2003), or the CYP 2C9 inhibitor, fluconazole (Scott et al. 2004a).

Lumiracoxib - an overview | ScienceDirect Topics

Lumiracoxib This carboxyl acid-containing agent has good oral availability and a short elimination t 1/2 , and, while achieving high synovial fluid concentrations relative to plasma that made it an effective pain reliever in osteoarthritis [253,254] , lumiracoxib was associated with hepatotoxicity that forced its withdrawal or contributed to its nonapproval in several major markets, including ...

Customer Service
1-866-799-3435 | Contact Form
Copyright © 2020 SaveRxCanada.to All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK